---
layout: default
title: Activated Charcoal Aloe Antimony Trisulfide Astacu
parent: 僅模型預測 (L5)
nav_order: 165
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Aloe Antimony Trisulfide Astacu
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Complex: No TxGNN Prediction — Repurposing Evaluation Incomplete

## One-Sentence Summary

This candidate is a 19-ingredient complex mixture with characteristics of a homeopathic preparation (including Lycopodium clavatum, Berberis aquifolium, Glycyrrhiza glabra, and bacterial components), with no market authorization in Taiwan and no DrugBank identifier assigned.
The TxGNN model returned **no repurposing predictions** for this compound; consequently, the standard repurposing evaluation cannot be completed under the current framework.
No supporting clinical trials or literature evidence were identified.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Unscored (prerequisite: no predictions generated) |
| Market Status | Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |

---

## Why This Candidate Could Not Be Evaluated

This compound is composed of 19 distinct ingredients spanning botanical extracts, minerals, animal-derived materials, and bacterial strains:

| Category | Ingredients |
|----------|-------------|
| Botanical / Herbal | Aloe, Berberis aquifolium root bark, Euphorbia resinifera resin, Fragaria vesca fruit, Glycyrrhiza glabra, Lycopodium clavatum spore, Medicago sativa whole |
| Mineral / Inorganic | Activated charcoal, Antimony trisulfide, Magnesium carbonate, Sodium carbonate, Zinc |
| Animal-Derived | Astacus astacus (crayfish), Bos taurus bile (cattle bile), Sus scrofa pancreas (porcine pancreas), Skim milk |
| Microbial | Escherichia coli, Proteus inconstans |
| Excipient | Sucrose |

The ingredient profile — particularly the combination of Lycopodium clavatum spores, Berberis aquifolium, bacterial lysates, and animal bile — is characteristic of a **complex homeopathic/naturopathic preparation**. Such multi-component mixtures typically lack a single well-defined molecular target or pharmacophore, making them structurally incompatible with the TxGNN knowledge graph model, which is designed to evaluate discrete molecular entities mapped to DrugBank identifiers.

No DrugBank ID was assigned (`null`), confirming the compound could not be anchored to the knowledge graph. This is the root cause of the empty prediction result.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned no repurposing predictions because this multi-component complex cannot be represented as a single knowledge-graph node; without a DrugBank ID and a defined pharmacological target, the model has no basis for generating predictions. Combined with zero market authorizations and absent safety data, there is insufficient information to proceed with any repurposing assessment.

**To proceed, the following is needed:**

- **Confirm product identity**: Verify whether this mixture corresponds to a known commercial homeopathic preparation (e.g., confirm brand name, manufacturer, and registered indication in any jurisdiction).
- **Disaggregate into evaluable components**: Consider running TxGNN separately on pharmacologically active single-entity components — for example:
  - **Berberine** (from *Berberis aquifolium*) — has a known DrugBank entry (DB04115) and existing repurposing literature
  - **Glycyrrhizin / Glycyrrhizinic acid** (from *Glycyrrhiza glabra*) — DrugBank DB13751
  - **Zinc** — DrugBank DB01593
- **Assign DrugBank IDs** for any evaluable component before re-submitting to the TxGNN pipeline.
- **Obtain safety and MOA data** for individual components via the TFDA package insert and DrugBank API before any clinical interpretation.
- **Determine regulatory scope**: If this is a homeopathic product, assess whether it falls under a separate regulatory pathway (e.g., OTC homeopathic exemption) rather than the standard NDA/drug approval route.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

